Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Abstract

Key Points Higher ibrutinib DI is associated with improved PFS, independent of del17p or TP53 mutation. Ibrutinib hold for >1 week, often needed to manage adverse events, is associated with increased PFS events.